Get the Stockscreener App
1.6801
1.21%
0.0201
Traws Pharma Inc stock is traded at $1.6801, with a volume of 24,176.
It is up +1.21% in the last 24 hours and up +41.18% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$1.66
Open:
$1.69
24h Volume:
24,176
Relative Volume:
0.02
Market Cap:
$10.35M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.69%
1M Performance:
+41.18%
6M Performance:
-67.75%
1Y Performance:
-85.39%
1-Day Range:
$1.65
$1.69
1-Week Range:
$1.6242
$1.8999
52-Week Range:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.6801 | 10.35M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
517.30 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.03 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.01 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Millennium Management LLC Buys New Holdings in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer - MSN
Traws Pharma (NASDAQ:TRAW) Trading 0.6% Higher – Here’s What Happened - Defense World
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MSN
Traws Pharma Inc. Stock Skyrockets Over 40%, Then Pares Gains in Volatile Trading - Daily Chhattisgarh News
Traws Pharma Stock (TRAW) Surges 55% on Positive Cancer Data - TipRanks
Traws Pharma (TRAW) Releases Promising Clinical Trial Results fo - GuruFocus
Traws Pharma Publishes Promising Phase 2 Study Results - TipRanks
Traws Pharma Announces Publication of Compelling Efficacy - GlobeNewswire
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - GlobeNewswire Inc.
Traws Pharma Receives FDA Feedback on Flu Drug Development - MSN
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir - GlobeNewswire
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - marketscreener.com
Traws Pharma advances flu drug development with FDA feedback - Investing.com India
Traws Pharma Announces Receipt Of FDA Guidance On Tivoxavir Marboxil, Plans For Pursuing Stockpiling For Pandemic Preparedness - marketscreener.com
Traws Pharma Receives FDA Guidance on Flu Treatment - TipRanks
Traws Pharma (TRAW) Gains FDA Insights on Flu Treatment Pathway | TRAW Stock News - GuruFocus
Traws Pharma advances flu drug development with FDA feedback By Investing.com - Investing.com Nigeria
FDA Advances Critical Bird Flu Drug Development as Ex-CDC Chief Warns of 50% Death Rate Risk - Stock Titan
Traws Pharma Unveils New Strategic Antiviral Focus - TipRanks
Traws Pharma’s Q1 2025 Results Highlight Progress and Profit - TipRanks
Traws Pharma Reports First Quarter 2025 Results And Business Highlights - marketscreener.com
Traws Pharma Reports Q1 2025 Financial Results - TipRanks
Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewswire
Traws Pharma Earnings Surge to $21.5M as Former CDC Director Backs Novel Flu and COVID Drug Pipeline - Stock Titan
Renaissance Technologies LLC Takes $89,000 Position in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
Geode Capital Management LLC Makes New $185,000 Investment in Traws Pharma, Inc. (NASDAQ:TRAW) - Defense World
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
TRAW stock touches 52-week low at $1.51 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $1.51 amid sharp annual decline - Investing.com India
Traws Pharma Appoints New Chairman Amid Leadership Changes - MSN
Traws Pharma appoints new interim CEO with compensation details By Investing.com - Investing.com Canada
Traws Pharma appoints new interim CEO with compensation details - Investing.com Australia
Traws Pharma announces $50 million stock offering potential - Investing.com Australia
Traws Pharma announces $50 million stock offering potential By Investing.com - Investing.com Canada
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Traws Pharma Inc Stock (TRAW) Financials Data
There is no financial data for Traws Pharma Inc (TRAW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):